Leland Gershell
Stock Analyst at Oppenheimer
(4.34)
# 432
Out of 4,761 analysts
123
Total ratings
41.07%
Success rate
27.41%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $56.07 | +35.54% | 1 | Dec 20, 2024 | |
| ARGX argenx SE | Reiterates: Outperform | $646 → $675 | $644.48 | +4.74% | 5 | Nov 21, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $190 → $180 | $152.43 | +18.09% | 10 | Nov 15, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $48 → $52 | $23.67 | +119.69% | 2 | Nov 11, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $135 → $147 | $120.67 | +21.82% | 2 | Nov 8, 2024 | |
| VERU Veru Inc. | Reiterates: Outperform | $5 | $0.57 | +773.06% | 8 | Nov 5, 2024 | |
| EPIX ESSA Pharma | Downgrades: Perform | n/a | $1.72 | - | 2 | Nov 4, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $65 → $73 | $46.13 | +58.25% | 8 | Oct 28, 2024 | |
| URGN UroGen Pharma | Reiterates: Outperform | $40 | $10.08 | +296.83% | 9 | Oct 16, 2024 | |
| IMVT Immunovant | Maintains: Outperform | $47 → $53 | $21.27 | +149.18% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $36.85 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $43 | $15.00 | +186.67% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $6.29 | +376.95% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.82 | +559.34% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $1.09 | +2,193.58% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $16.27 | +72.10% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.72 | +572.04% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $37.46 | +94.87% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $2.35 | +751.06% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $21.62 | +34.14% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $8.44 | +314.69% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $1.32 | +657.58% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.75 | +33.33% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $4.60 | +95.65% | 2 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.34 | +1,392.54% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $250.59 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $2.04 | +537.25% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $0.47 | +756.35% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $68.25 | - | 2 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.43 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7,200 | $4.35 | +165,417.24% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $16.74 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.45 | +1,940.82% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $0.59 | - | 5 | Mar 31, 2020 |
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $56.07
Upside: +35.54%
argenx SE
Nov 21, 2024
Reiterates: Outperform
Price Target: $646 → $675
Current: $644.48
Upside: +4.74%
Ascendis Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $190 → $180
Current: $152.43
Upside: +18.09%
Dianthus Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $23.67
Upside: +119.69%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $120.67
Upside: +21.82%
Veru Inc.
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.57
Upside: +773.06%
ESSA Pharma
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.72
Upside: -
Soleno Therapeutics
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $46.13
Upside: +58.25%
UroGen Pharma
Oct 16, 2024
Reiterates: Outperform
Price Target: $40
Current: $10.08
Upside: +296.83%
Immunovant
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $21.27
Upside: +149.18%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $36.85
Upside: -
Sep 25, 2024
Maintains: Outperform
Price Target: $15 → $43
Current: $15.00
Upside: +186.67%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $6.29
Upside: +376.95%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.82
Upside: +559.34%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $1.09
Upside: +2,193.58%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $16.27
Upside: +72.10%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.72
Upside: +572.04%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $37.46
Upside: +94.87%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $2.35
Upside: +751.06%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $21.62
Upside: +34.14%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $8.44
Upside: +314.69%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $1.32
Upside: +657.58%
Mar 28, 2024
Initiates: Outperform
Price Target: $5
Current: $3.75
Upside: +33.33%
Mar 21, 2024
Maintains: Outperform
Price Target: $9
Current: $4.60
Upside: +95.65%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.34
Upside: +1,392.54%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $250.59
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $2.04
Upside: +537.25%
Mar 24, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $0.47
Upside: +756.35%
Feb 22, 2023
Downgrades: Perform
Price Target: n/a
Current: $68.25
Upside: -
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.43
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $7,200
Current: $4.35
Upside: +165,417.24%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $16.74
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $2.45
Upside: +1,940.82%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $0.59
Upside: -